作者
Chung-Han Lee, Martin H Voss, Maria Isabel Carlo, Ying-Bei Chen, Mark Zucker, Andrea Knezevic, Robert A Lefkowitz, Natalie Shapnik, Chloe Dadoun, Ed Reznik, Neil J Shah, Colette Ngozi Owens, Deaglan Joseph McHugh, David Henry Aggen, Andrew Leonard Laccetti, Ritesh Kotecha, Darren R Feldman, Robert J Motzer
发表日期
2022/7/20
期刊
Journal of Clinical Oncology
卷号
40
期号
21
页码范围
2333-2341
出版商
Wolters Kluwer Health
简介
PURPOSE
To assess the efficacy and safety of cabozantinib plus nivolumab in a phase II trial in patients with non–clear-cell renal cell carcinoma (RCC).
PATIENTS AND METHODS
Patients had advanced non–clear-cell renal carcinoma who underwent 0-1 prior systemic therapies excluding prior immune checkpoint inhibitors. Patients received cabozantinib 40 mg once daily plus nivolumab 240 mg once every 2 weeks or 480 mg once every 4 weeks. Cohort 1 enrolled patients with papillary, unclassified, or translocation-associated RCC; cohort 2 enrolled patients with chromophobe RCC. The primary end point was objective response rate (ORR) by RECIST 1.1; secondary end points included progression-free survival, overall survival, and safety. Next-generation sequencing results were correlated with response.
RESULTS
A total of 47 patients were treated with a median follow-up of 13.1 months. Objective response …
学术搜索中的文章
CH Lee, MH Voss, MI Carlo, YB Chen, M Zucker… - Journal of Clinical Oncology, 2022